Cara Therapeutics | CARA - Ebitda


Cara Therapeutics reported $-2.39M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Chugai Pharma JPY 169.01B 12.52B Dec/2025
Cipla INR 12.55B 6.4B Dec/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
J&J USD 9.52B 389M Sep/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Pacira USD 38.71M 10.65M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
RedHill Biopharma USD 2.69M 108.46M Jun/2023
Supernus Pharmaceuticals USD 48.5M 6.6M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024